Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections

International Journal of Antimicrobial Agents

Volumn 34, Issue 6, 2009, Pages 575-579

  Erbay, Ayşe ^a   Idil, Aysun ^b   Gözel, M Gökhan ^a   Mumcuoǧlu, Ipek ^a   Balaban, Neriman ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Acinetobacter baumannii; Antimicrobial therapy; Appropriateness; Mortality

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL SURVIVAL; BLOOD CULTURE; BLOODSTREAM INFECTION; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; THERAPY DELAY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350412317     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.07.006     Document Type: Article

References (17)

1. Cisneros J.M., and Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 8 (2002) 687-693
2. Seifert H., Strate A., and Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 74 (1995) 340-349
3. Falagas M.E., and Rafailidis P.I. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 11 (2007) 134
4. Falagas M.E., Kasiakou S.K., Rafailidis P.I., Zouglakis G., and Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteremia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 57 (2006) 1251-1254
5. Maragakis L.L., and Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46 (2008) 1254-1263
6. Robenshtok E., Paul M., Leibovici L., Fraser A., Pitlik S., Ostfeld I., et al. The significance of Acinetobacter baumannii bacteremia compared with Klebsiella pneumoniae bacteremia: risk factors and outcomes. J Hosp Infect 64 (2006) 282-287
7. Jerassy Z., Yinnon A.M., Mazouz-Cohen S., Benenson S., Schlesinger Y., Rudensky B., et al. Prospective hospital-wide studies of 505 patients with nosocomial bacteremia in 1997 and 2002. J Hosp Infect 62 (2006) 230-236
8. Grupper M., Sprecher H., Mashiach T., and Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 28 (2007) 293-298
9. Kollef M.H. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 47 Suppl. 1 (2008) S3-S13
10. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., and Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 115 (2003) 529-535
11. Kwon K.T., Oh W.S., Song J.H., Chang H.H., Jung S.I., Kim S.W., et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteremia. J Antimicrob Chemother 59 (2007) 525-530
12. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 (1988) 128-140
13. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 13 (1985) 818-829
14. Choi J.Y., Park Y.S., Kim C.O., Park Y.S., Yoon H.J., Shin S.Y., et al. Mortality risk factors of Acinetobacter baumannii bacteremia. Intern Med J 35 (2005) 599-603
15. Kuo L.C., Lai C.C., Liao C.H., Hsu C.K., Chang Y.L., Chang C.Y., et al. Multidrug-resistant Acinetobacter baumannii bacteremia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 13 (2007) 196-198
16. Sunenshine R.H., Wright M.O., Maragakis L.L., Harris A.D., Song X., Hebden J., et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13 (2007) 97-103
17. Chen H.P., Chen T.L., Lai C.H., Fung C.P., Wong W.W., Yu K.W., et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 38 (2005) 127-136